A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of BIIB059 in Participants With Active Cutaneous Lupus Erythematosus With or Without Systemic Manifestations. Register Today!
